Genetics of cholesterol efflux

Area of Science:

• Genetics
• Cardiovascular Disease
• Metabolic Disorders

Background:

• Plasma high-density lipoprotein cholesterol (HDL-C) levels are inversely associated with coronary heart disease (CHD).
• HDL-C is a heritable trait (40-60%) and a potential therapeutic target due to its cardioprotective effects.
• Cellular cholesterol efflux is the rate-limiting step in HDL biogenesis and is crucial for maintaining cholesterol homeostasis.

Purpose of the Study:

• To review the genetic basis of cellular cholesterol efflux, a key process in HDL biogenesis.
• To explore the genetic determinants influencing HDL-C levels and their link to CHD.
• To integrate findings from various genetic studies and recent miRNA research in cholesterol metabolism.

Main Methods:

• Integration of data from family studies and linkage analyses.
• Analysis of genome-wide association studies (GWAS).
• Review of recent literature on micro-RNAs (miRNAs) in cellular cholesterol metabolism.

Main Results:

• Monogenic disorders, such as Tangier disease (ABCA1 mutations), impair HDL biogenesis.
• Disorders of cellular cholesterol homeostasis often lead to reduced HDL-C levels.
• Genomic pathways regulating HDL metabolism are being identified, including miRNA involvement.

Conclusions:

• Genetic factors play a substantial role in determining HDL-C levels and influencing CHD risk.
• Understanding the genetics of cellular cholesterol efflux is vital for developing novel therapies.
• Targeting cellular cholesterol efflux pathways may offer a new strategy for preventing atherosclerosis.